Artelo Biosciences Announces Publication Of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness In Treating And Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological